Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science. The huge, complex structures of these drugs don’t just look extraordinary in the 3-D modeling systems used to design them; they also perform their jobs remarkably well, offering high efficacy and few side effects. And there is much more to come: existing treatment archetypes are evolving and becoming more sophisticated all the time, and continuing research is yielding entirely new types of products.
Learn How to Get Seed Funding Investment for Your Business from the Government! Featuring SBIR program managers from leading Federal agencies invited including DOD, NIH, NCI, and Homeland Security plus case studies from experienced SBIR recipients and much more! Network with the SBIR program managers during an Expo and meet other business owners.
This event is generously supported by Johns Hopkins University Montgomery County; Maryland Technology Development Corporation; BioHealth Innovation; and the Montgomery County Department of Economic Development.
Eyeing the biotech IPO boom earlier this year, Ariosa Diagnostics planned to go public as it battled larger competitors in the prenatal testing field. But the San Jose, CA-based company backed off in late April, and that was its last chance. Multinational healthcare firm Roche has bought Ariosa for an undisclosed amount, the companies announced today.
Most people’s to-do lists are, almost by definition, pretty dull, filled with those quotidian little tasks that tend to slip out of our minds. Pick up the laundry. Get that thing for the kid. Buy milk, canned yams and kumquats at the local market.
A quick note: Nature announced yesterday that it will make all of its articles free to view, read, and annotate online. That applies to the historic science journal (launched in 1869) and to 48 other scientific journals in Macmillan’s Nature Publishing Group (NPG). Other titles include Nature Genetics, Nature Medicine and Nature Physics.
Federal spending on scientific research hasn’t kept up with inflation in recent years, and it’s made it harder for researchers to fund their work. Some of them are turning to another source: crowdfunding. But this funding source raises new questions for scientists.
“Today, on this stage in the auditorium of Richard Montgomery High School – a magnet school that symbolizes the quality education that is Montgomery County – I stand before you with great humility and excitement about the future as I begin my third term as your County Executive.”
“I have learned throughout my life that families are our “links” to our past, our anchors in the present, and bridges to our future. So, to my family, your love, support and patience have kept me grounded.”
Every once and a while we get a clear example of the gulf between those battling over important public policy issues and can understand why the public and policy makers are confused by resulting charges and counter charges. Last week was a good illustration.
The Washington Business Journal interviewed Leslie Ford Weber, JHU’s director of the Montgomery County Campus and of government and community affairs for Montgomery County. The feature ran as an Executive Profile on Nov. 14, 2014. It was written by Vandana Sinha, an assistant managing editor at the Washington Business Journal. The photo was taken by Joanne S. Lawton.
That next blockbuster drug? It all begins with a hypothesis: GlaxoSmithKline just announced the winners of its second Discovery Fast Track Challenge – a competition that teams up American and European academia with GSK researchers to speed up their search for new therapeutics.
